Investor Relations.

Trendlines invests in, and incubates innovation-based medtech and agrifood technologies.

As intensely hands-on investors, we are involved in all aspects of our portfolio companies from technology development to business building.

For Corporate Governance please press the form Reset button.
14 Sep, 2022 Investment by Agriline Ltd. and Trendlines in Three Trendlines Portfolio Companies
31 Aug, 2022 August 2022 Monthly Update
18 Aug, 2022 SGM Minutes and Q&A
11 Aug, 2022 Appointment of Independent Director and Changes to the Board – Prof Low
11 Aug, 2022 Investments by Agriline Ltd. and Trendlines in Three Trendlines Portfolio Companies
10 Aug, 2022 H1 2022 Unaudited Financial Results Press Release
10 Aug, 2022 H1 2022 Unaudited Financial Results
10 Aug, 2022 H1 2022 Earnings Call Presentation & Recording
02 Aug, 2022 Cessation of Nir Goldenberg as CEO Trendlines Innovation Labs
01 Aug, 2022 July 2022 Monthly Update
27 Jul, 2022 Profit Warning Guidance – H12022
20 Jul, 2022 SGM Results 20 July 2022
19 Jul, 2022 Earnings Call H1 2022
19 Jul, 2022 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)
15 Jul, 2022 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)
14 Jul, 2022 Write-off of Portfolio Company Stimatix GI Ltd.
12 Jul, 2022 Completion of the Third Tranche of the Proposed Subscription
30 Jun, 2022 June 2022 Monthly Update
28 Jun, 2022 SGM Notice – 20 July 2022
28 Jun, 2022 SGM Circular
06 Jun, 2022 Change – Announcement of Appointment
06 Jun, 2022 Appointment of Independent Director – Nehama Ronen
24 May, 2022 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)
13 May, 2022 AGM April 2022 Minutes
13 May, 2022 SGM April 2022 Minutes
04 May, 2022 April 2022 Monthly Update
30 Apr, 2022 Investor Presentation April 2022
25 Apr, 2022 Correction to the Company’s Announcement Dated 11 April 2022
19 Apr, 2022 Changes to the Composition of Board and Board Committees
19 Apr, 2022 Disclosure of Interest of Director – Steve Rhodes
19 Apr, 2022 Disclosure of Interest of Director – Todd Dollinger
19 Apr, 2022 Disclosure of Interest of Director – Elka Nir
19 Apr, 2022 Disclosure of Interest of Director – Hang Chang Chieh
19 Apr, 2022 Disclosure of Interest of Director – Sin Boon Ann
19 Apr, 2022 Disclosure of Interest of Director – Zeev Bronfeld
18 Apr, 2022 Changes in Percentage Level of Substantial Shareholder
16 Apr, 2022 Grant of Options to Directors
14 Apr, 2022 Receipt of Second Anniversary Payment from ApiFix Acquisition
13 Apr, 2022 Results of AGM
13 Apr, 2022 Results of SGM
12 Apr, 2022 Changes in Percentage Level of Substantial Shareholder
11 Apr, 2022 Response to Queries from the Securities Investors Association (Singapore) on the Annual Report
04 Apr, 2022 Completion of the Second Tranche of the Proposed Subscription
04 Apr, 2022 Changes in Percentage Level of Substantial Shareholder
01 Apr, 2022 SGM Minutes
31 Mar, 2022 March 2022 Monthly Update
25 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
23 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
22 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
21 Mar, 2022 Completion of the First Tranche of the Proposed Subscription
18 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
16 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
16 Mar, 2022 Changes in Percentage Level of Substantial Shareholder
14 Mar, 2022 Partial Completion of the First Tranche of the Proposed Subscription
09 Mar, 2022 Retirement of Independent Director
08 Mar, 2022 FY 2021 Annual Report
08 Mar, 2022 Notice of AGM
08 Mar, 2022 Circular and Notice of SGM
04 Mar, 2022 March SGM Results Announcement
22 Feb, 2022 H2 2021 and FY 2021 Unaudited Financial Results
22 Feb, 2022 FY 2021 Financial Results Press Release
04 Feb, 2022 Listing & Quotation of Proposed Subscription Agreement
31 Jan, 2022 January 2022 Monthly Update
28 Jan, 2022 SGM Circular & Notice
20 Jan, 2022 Proposed Subscription Agreement Press Release
19 Jan, 2022 Proposed Subscription Agreement Announcement
04 Jan, 2022 Grant of Options
03 Jan, 2022 December 2021 Monthly Update
03 Jan, 2022 December 2018 Monthly Update
02 Dec, 2021 November 2021 Monthly Update
01 Dec, 2021 Completion of OrthoSpin Ltd. Acquisition by Synthes GMBH
29 Nov, 2021 Investor Presentation November 2021
24 Nov, 2021 Entry into Interested Person Transaction with Agriline Limited
23 Nov, 2021 Invitation to Business Update Event (Virtual)
04 Nov, 2021 Press release: Trendlines Announces Acquisition of Portfolio Company OrthoSpin Ltd.
04 Nov, 2021 Announcement: Acquisition of Trendlines’ Portfolio Company OrthoSpin Ltd. by Synthes GMBH
01 Nov, 2021 October 2021 Monthly Update
04 Oct, 2021 September 2021 Monthly Update
30 Sep, 2021 Trendlines to Present at Lytham Partners Fall 2021 Investor Conference
02 Sep, 2021 Investor Presentation September 2021
01 Sep, 2021 August 2021 Monthly Update
11 Aug, 2021 H1 2021 Unaudited Financial Results
11 Aug, 2021 H1 2021 Financial Results Press Release
11 Aug, 2021 H1 2021 Earnings Call Presentation
02 Aug, 2021 July 2021 Monthly Update
22 Jul, 2021 Discontinuation of Proposed Dual Primary Listing
01 Jul, 2021 June 2021 Monthly Update
24 Jun, 2021 Q1 2021 Unaudited Financial Results
24 Jun, 2021 Q1 2021 Financial Results Press Release
14 Jun, 2021 Announcement of Dividend Policy
04 Jun, 2021 May 2021 Monthly Update
03 Jun, 2021 Trendlines Agrifood Fund Invests in PlanetWatchers
21 May, 2021 SGM April 2021 Minutes
21 May, 2021 AGM 2021 Minutes
03 May, 2021 April 2021 Monthly Update
29 Apr, 2021 Signing of Letter of Intent
22 Apr, 2021 SGM April 2021 Results
22 Apr, 2021 AGM 2021 Results
22 Apr, 2021 AGM 2021 Presentation
19 Apr, 2021 Questions and Answers Ahead of Upcoming AGM and SGM
08 Apr, 2021 Change of Joint Company Secretary
06 Apr, 2021 March 2021 Monthly Update
06 Apr, 2021 Receipt of a Non-Binding Letter of Intent
05 Apr, 2021 Trendlines to Seek Dual Primary Listing in Tel Aviv
16 Mar, 2021 Replacement SGM Circular and Related Documents
16 Mar, 2021 SGM Circular and Notice
16 Mar, 2021 Notice of AGM 2021 and Related Documents
16 Mar, 2021 FY 2020 Annual Report
02 Mar, 2021 February 2021 Monthly Update
23 Feb, 2021 FY 2020 Unaudited Financial Statements
23 Feb, 2021 FY 2020 Financial Results Press Release
23 Feb, 2021 FY 2020 Investor Presentation
01 Feb, 2021 January 2021 Monthly Update
06 Jan, 2021 December 2020 Monthly Update
06 Jan, 2021 Incorporation of Portfolio Companies Considered Subsidiaries
30 Dec, 2020 Proposed Technical Merger
30 Nov, 2020 November 2020 Monthly Update
23 Nov, 2020 NHG and TMS Ink New Deal and Expand Collaboration Scope
12 Nov, 2020 Investment in Quoted Securities
02 Nov, 2020 October 2020 Monthly Update
29 Oct, 2020 Investment in Quoted Securities
20 Oct, 2020 Shareholder Update Presentation October 2020
01 Oct, 2020 September 2020 Monthly Update
03 Sep, 2020 August 2020 Monthly Update
02 Sep, 2020 Investments in Four Trendlines’ Portfolio Companies
13 Aug, 2020 H1 2020 Earnings Call Presentation
12 Aug, 2020 Changes in Composition of Board Committees
11 Aug, 2020 H1 2020 Financial Results Press Release
11 Aug, 2020 H1 2020 Unaudited Financial Results
11 Aug, 2020 H1 2020 Investor Presentation
04 Aug, 2020 July 2020 Monthly Update
02 Jul, 2020 June 2020 Monthly Update
24 Jun, 2020 Disclosure of Interest – Executive Officers
24 Jun, 2020 SGM 2020 Minutes
24 Jun, 2020 AGM 2020 Minutes
23 Jun, 2020 Grant of Options
17 Jun, 2020 SGM Results
17 Jun, 2020 AGM Results
17 Jun, 2020 Appointment of Independent Director – Sin Boon Ann
17 Jun, 2020 Appointment of Independent Director – Sin Boon Ann & Background
17 Jun, 2020 AGM 2020 Presentation
12 Jun, 2020 Questions and Answers Ahead of Upcoming AGM and SGM
01 Jun, 2020 May 2020 Monthly Update
14 May, 2020 Business Update on the Impact of Covid-19
12 May, 2020 Adjournment of Annual General Meeting
12 May, 2020 Extraordinary / Special General Meeting
05 May, 2020 April 2020 Monthly Update
05 May, 2020 Notice of Adjourned Annual General Meeting
21 Apr, 2020 Update on Annual Report 2019 Print Copies
16 Apr, 2020 Change to Half-Yearly Reporting
07 Apr, 2020 Q&A on ApiFix Acquisition Conference Call Presentation
03 Apr, 2020 Additional Information Regarding the Acquisition of Portfolio Company ApiFix Ltd.
02 Apr, 2020 ApiFix Acquired By OrthoPediatrics
02 Apr, 2020 March 2020 Monthly Update
26 Mar, 2020 Notice of AGM
26 Mar, 2020 FY 2019 Annual Report
17 Mar, 2020 Approval from the SGX for extension of time to hold the AGM
06 Mar, 2020 Application for postponement of the AGM
03 Mar, 2020 February 2020 Monthly Update
03 Mar, 2020 Investor Presentation March 2020
27 Feb, 2020 Agriline and Trendlines Invest in Portfolio Company
27 Feb, 2020 Grant of Options
24 Feb, 2020 FY 2019 Results Press Release
24 Feb, 2020 FY 2019 Unaudited Financial Results
17 Feb, 2020 Investments by Agriline and Trendlines in 7 Portfolio Companies
04 Feb, 2020 Changes in Percentage Level of Substantial Shareholder
03 Feb, 2020 January 2020 Monthly Update
13 Jan, 2020 Signing a non-binding letter of intent
07 Jan, 2020 December 2019 Monthly Update
07 Jan, 2020 Bayer Trendlines Ag Innovation Fund Co-invests with Trendlines in ProJini Agchem
02 Jan, 2020 Response to SGX query regarding trading activity
26 Dec, 2019 Changes in Percentage Level of Substantial Shareholders
23 Dec, 2019 Listing & Quotation of Rights Shares
19 Dec, 2019 Results of the Rights Issue
19 Dec, 2019 Disclosure of Director’s Interest
03 Dec, 2019 November 2019 Monthly Update
28 Nov, 2019 Rights Issue – Lodgement of Offer Information Statement
28 Nov, 2019 Investor Presentation November 2019
19 Nov, 2019 SGM Results
19 Nov, 2019 Rights Issue – Book Closure Date Announcement
18 Nov, 2019 Shareholder Presentation ahead of SGM – Agrifood Fund Update
14 Nov, 2019 Agrifood Fund Agreement Signed
07 Nov, 2019 Q3 2019 Earnings Press Release
07 Nov, 2019 Q3 2019 Unaudited Financial Results
07 Nov, 2019 Q3 2019 Earnings Call Presentation
31 Oct, 2019 October 2019 Monthly Update
25 Oct, 2019 Notice of SGM and Circular
22 Oct, 2019 Rights Issue – Additional Listing Application
03 Oct, 2019 September 2019 Monthly Update
03 Oct, 2019 Response to SGX Queries on Proposed Rights Issue
26 Sep, 2019 Rights Issue Announcement
24 Sep, 2019 Trendlines Announces Investment Commitments in Agrifood Fund
02 Sep, 2019 August 2019 Monthly Update
29 Aug, 2019 Incorporation of Nasotrak Medical as Subsidiary
28 Aug, 2019 ApiFix Receives FDA Approval
22 Aug, 2019 Investor Presentation August 2019
15 Aug, 2019 Incorporation of Szone Medical as Subsidiary
08 Aug, 2019 Changes/Disclosure of Interest of Substantial Shareholders
07 Aug, 2019 Q2 2019 Earnings Press Release
07 Aug, 2019 Q2 2019 Unaudited Financial Results
07 Aug, 2019 Q2 2019 Earnings Call Presentation
06 Aug, 2019 Completion of Placement
01 Aug, 2019 July 2019 Monthly Update
29 Jul, 2019 Listing & Quotation Notice on Placement
22 Jul, 2019 Trendlines and Librae Sign SGD10.88 Million Investment Agreement
22 Jul, 2019 Trendlines and Librae Sign Placement Proposal Agreement
19 Jul, 2019 Trendlines Secures Commitment for New Fund
10 Jul, 2019 Bayer Trendlines Ag Innovation Fund Makes Second Investment
01 Jul, 2019 June 2019 Monthly Update
18 Jun, 2019 5 Portfolio Companies Awarded Horizon 2020 Grants
03 Jun, 2019 May 2019 Monthly Update
23 May, 2019 Investor Presentation May 2019
13 May, 2019 Q1 2019 Earnings Press Release
13 May, 2019 Q1 2019 Unaudited Financial Results
13 May, 2019 Q1 2019 Earnings Call Presentation
02 May, 2019 April 2019 Monthly Update
29 Apr, 2019 AGM Results and Presentation
29 Apr, 2019 AGM 2019 Presentation
25 Apr, 2019 Dividend Distribution to Stimatix Shareholders
09 Apr, 2019 Correction to Annual Report FY2018
01 Apr, 2019 March 2019 Monthly Update
20 Mar, 2019 Stimatix Product Website Launch
20 Mar, 2019 Notice of AGM
20 Mar, 2019 Annual Report Print Request Form
20 Mar, 2019 FY 2018 Annual Report
04 Mar, 2019 February 2019 Monthly Update
27 Feb, 2019 Incorporation of Subsidiairies
26 Feb, 2019 Grant of Options
20 Feb, 2019 FY 2018 Earnings Press Release
20 Feb, 2019 FY 2018 Unaudited Financial Results
20 Feb, 2019 Investor Presentation February 2019
20 Feb, 2019 FY 2018 Earnings Call Presentation
13 Feb, 2019 SGM Results & Presentation
11 Feb, 2019 Leviticus Cardio Announces Successful FIH
07 Feb, 2019 January 2019 Monthly Update
30 Jan, 2019 Management Changes to Strengthen and Accelerate Investment Activities
30 Jan, 2019 Appointment of Nir Goldenberg as CEO Trendlines Labs
30 Jan, 2019 Cessation of Yosef Hazan as CEO Trendlines Labs
30 Jan, 2019 Appointment of Barak Singer as CEO Trendlines Incubators Israel
30 Jan, 2019 Cessation of Nitza Kardish PhD as CEO Trendlines Incubators Israel
24 Jan, 2019 Trendlines Medical Singapore Delivers Partnership Outcomes
24 Jan, 2019 Incorporation of Portfolio Companies Considered Subsidiaries
23 Jan, 2019 10 Companies to Watch Report January 2019
15 Jan, 2019 SEEDS Capital Names Trendlines Co-Investment Partner
07 Jan, 2019 SGM
18 Dec, 2018 Trendlines to Launch Agrifood Tech Center in Singapore
03 Dec, 2018 November 2018 Monthly Update
14 Nov, 2018 Sustainability Report 2017
12 Nov, 2018 Grant of Options
11 Nov, 2018 Trendlines Medical Singapore and A*ccelerate Partner
08 Nov, 2018 Q3 2018 Earnings Press Release
08 Nov, 2018 Q3 2018 Unaudited Financial Results
08 Nov, 2018 Q3 2018 Unaudited Financial Results
08 Nov, 2018 Q3 2018 Earnings Call Presentation
08 Nov, 2018 Investor Presentation November 2018
01 Nov, 2018 October 2018 Monthly Update
24 Oct, 2018 10 Companies to Watch Report October 2018
03 Oct, 2018 September 2018 Monthly Update
04 Sep, 2018 August 2018 Monthly Update
04 Sep, 2018 Investor Presentation September 2018
08 Aug, 2018 Cessation of Company’s VP Business Development
07 Aug, 2018 Q2 2018 Earnings Press Release
07 Aug, 2018 Q2 Unaudited Financial Statements
07 Aug, 2018 Q2 2018 Unaudited Financial Results
07 Aug, 2018 Q2 2018 Earnings Call Presentation
31 Jul, 2018 July 2018 Monthly Update
26 Jul, 2018 10 Companies to Watch Report July 2018
24 Jul, 2018 Termination of Term Sheet and Joint Venture Agreement
23 Jul, 2018 OrthoSpin Announces US$3 Million Investment from J&J
10 Jul, 2018 Haim Brosh Named CFO
10 Jul, 2018 Appointment of Haim Brosh as CFO, Joint Company Secretary and Compliance Officer
05 Jul, 2018 ViAqua Therapeutics Completes Investment from Nutreco
04 Jul, 2018 June 2018 Monthly Update
19 Jun, 2018 Arcuro Medical Announces FDA Clearance
12 Jun, 2018 Press Release on Management Changes
12 Jun, 2018 Cessation of CFO and Joint Company Secretary and Appointment of Interim CFO
12 Jun, 2018 Announcement of Cessation of CFO and Joint Company Secretary
05 Jun, 2018 May 2018 Monthly Update
31 May, 2018 Trendlines and Sirius VC Sign Co-investment Agreement
24 May, 2018 Investor Presentation May 2018
09 May, 2018 Q1 2018 Earnings Press Release
09 May, 2018 Q1 2018 Unaudited Financial Statements
09 May, 2018 Q1 2018 Unaudited Financial Results
09 May, 2018 Q1 2018 Earnings Call Presentation
02 May, 2018 April 2018 Monthly Update
25 Apr, 2018 Annual General Meeting Results and Presentation
25 Apr, 2018 Special General Meeting Results
23 Apr, 2018 10 Companies to Watch Report April 2018
16 Apr, 2018 BioFishency Significantly Increases Sales in 2018
09 Apr, 2018 Trendlines Discloses 2014 Asset Purchase Agreement Details
03 Apr, 2018 March 2018 Monthly Update
21 Mar, 2018 Trendlines and Nutreco Sign Collaboration MOU
20 Mar, 2018 Notice of Special General Meeting and Circular to Shareholders
20 Mar, 2018 Notice of Annual General Meeting
20 Mar, 2018 FY 2017 Annual Report
07 Mar, 2018 Investor Presentation March 2018
28 Feb, 2018 February 2018 Monthly Update
26 Feb, 2018 Saturas Completes US$4 Million Investment Round
22 Feb, 2018 FY 2017 Earnings Call Presentation
21 Feb, 2018 FY2017 Earnings Press Release
21 Feb, 2018 FY2017 Unaudited Financial Statements
21 Feb, 2018 FY 2017 Unaudited Financial Results
08 Feb, 2018 Trendlines Medical Singapore Selected for Startup SG Equity Program
31 Jan, 2018 January 2018 Monthly Update
18 Jan, 2018 10 Companies to Watch Report Jan 2018
03 Jan, 2018 STS Medical Receives FDA Clearance
02 Jan, 2018 ApiFix Announces Management Changes
28 Dec, 2017 December 2017 Monthly Update
30 Nov, 2017 November 2017 Monthly Update
16 Nov, 2017 National Healthcare Group and Trendlines Enter into MOU
13 Nov, 2017 Trendlines Exits MitrAssist
13 Nov, 2017 Consummation of MitrAssist Exit
12 Nov, 2017 Cessation of COO and Joint Company Secretary
10 Nov, 2017 Q3 2017 Earnings Call Presentation
09 Nov, 2017 Q3 2017 Earnings Press Release
09 Nov, 2017 Q3 2017 Unaudited Financial Results
09 Nov, 2017 Investor Presentation Nov 2017
08 Nov, 2017 Purchase of Shares by Directors
31 Oct, 2017 October 2017 Monthly Update
30 Oct, 2017 Response to SGX Queries Re Trading Activity
30 Oct, 2017 Dividend Policy
30 Oct, 2017 Strategic Review and Expenses Reduction Plan
26 Oct, 2017 Change of % Interest of Substantial Shareholders
25 Oct, 2017 Completion of Proposed S$14 Million Placement
25 Oct, 2017 Trendlines Raises S$14 Million in Share Placement
20 Oct, 2017 Proposed Placement
19 Oct, 2017 10 Companies to Watch Report Oct 2017
16 Oct, 2017 Trendlines Singapore Medical Makes First Investment
16 Oct, 2017 September 2017 Monthly Update
15 Oct, 2017 Incorporation of Portfolio Company as Subsidiary
10 Oct, 2017 Purchase of Shares by Directors
10 Oct, 2017 Placement Announcement
18 Sep, 2017 Trendlines and Haier Sign MOU
07 Sep, 2017 Purchase of Shares by Directors
04 Sep, 2017 August 2017 Monthly Update
30 Aug, 2017 Sale of Holdings in Mitrassist
21 Aug, 2017 Press Release on Trendlines-Shoushan Wealth Joint Venture Agreement
21 Aug, 2017 Definitive Joint Venture Agreement between Trendlines and Shoushan Wealth Holdings
16 Aug, 2017 Investor Presentation August 2017
10 Aug, 2017 Purchase of Shares by Directors
07 Aug, 2017 Q2 2017 Earnings Press Release and FAQs
07 Aug, 2017 Q2 2017 Unaudited Financial Results
02 Aug, 2017 July 2017 Monthly Update
12 Jul, 2017 10 Companies to Watch Report July 2017
09 Jul, 2017 Purchase of Shares by Directors
05 Jul, 2017 10 Companies to Watch Report
03 Jul, 2017 June 2017 Monthly Update
27 Jun, 2017 Bayer Trendlines Ag Innovation Fund Makes First Investment
16 Jun, 2017 Trendlines Completes Sale of BioSight
15 Jun, 2017 Consummation of BioSight Exit
12 Jun, 2017 Most Valuable Company’s Product on Schedule
08 Jun, 2017 Purchase of Shares by Directors
06 Jun, 2017 May 2017 Monthly Update
06 Jun, 2017 Trendlines Exits BioSight - Announcement
06 Jun, 2017 Trendlines Exits BioSight - Press Release
15 May, 2017 Investor Presentation May 2017
10 May, 2017 Q1 2017 Earnings Press Release
10 May, 2017 Q1 2017 Unaudited Financial Results
09 May, 2017 Purchase of Shares by Directors
05 May, 2017 Q1 2017 Earnings Conference Call
03 May, 2017 April 2017 Monthly Update
27 Apr, 2017 AGM 2017 Presentation
26 Apr, 2017 AGM Results
26 Apr, 2017 SGM Results
18 Apr, 2017 Information on AGM and SGM Agenda
07 Apr, 2017 Purchase of Shares by Directors
06 Apr, 2017 Grant of Options
04 Apr, 2017 March 2017 Monthly Update
29 Mar, 2017 Trendlines Labs Receives Grant from SIIRD for Clinical Trials in Singapore
20 Mar, 2017 Notice of AGM
20 Mar, 2017 Notice of SGM and Circular
20 Mar, 2017 FY 2016 Annual Report
08 Mar, 2017 Purchase of Shares by Directors
01 Mar, 2017 February 2017 Monthly Update
27 Feb, 2017 Grant of Waiver
23 Feb, 2017 Opening of Trendlines Medical Singapore
22 Feb, 2017 FY2016 Earnings Press Release
22 Feb, 2017 FY 2016 Unaudited Financial Results
22 Feb, 2017 Investor Presentation February 2017
13 Feb, 2017 Trendlines Celebrates Ten Years
07 Feb, 2017 Purchase of Shares by Directors
01 Feb, 2017 January 2017 Monthly Update
24 Jan, 2017 The Trendlines Group to Present at Noble Capital Markets 13th Annual Investor Conference
16 Jan, 2017 Trendlines Medical Singapore Receives S$2.2 Million Grant from SPRING Singapore
16 Jan, 2017 Trendlines Medical Singapore Receives S$2.2 Million Grant from SPRING Singapore -PR
10 Jan, 2017 Purchase of Shares by Directors/Chief Executive Officers
05 Jan, 2017 December 2016 Monthly Update
04 Jan, 2017 PrimePartners Corporate Finance Holdings Invests in Trendlines Medical
04 Jan, 2017 Execution of Share Purchase Agreement
30 Dec, 2016 Completion of Allotment and Issuance of Shares by Trendlines Medical Singapore
21 Dec, 2016 B. Braun Melsungen AG Invests in Trendlines Medical Singapore
21 Dec, 2016 Definitive Agreement between B. Braun Melsungen AG and Trendlines Medical Singapore
18 Dec, 2016 Venture Capital Fund and China Joint Venture
13 Dec, 2016 Disclosure of Changes in Interests of Directors
07 Dec, 2016 Gordian Surgical Completes Raise and Receives FDA
01 Dec, 2016 November 2016 Update
28 Nov, 2016 B. Braun/Trendlines Partnership Leads to ApiFix Investment
23 Nov, 2016 Change of Subsidiary Name
09 Nov, 2016 Q3 2016 Earnings Press Release
09 Nov, 2016 Q3 2016 Investor Presentation
08 Nov, 2016 Q3 2016 Unaudited Financial Results
07 Nov, 2016 Notification of Q3 2016 Results Conference Call
03 Nov, 2016 October 2016 Update
13 Oct, 2016 Approval of Trendlines Medical Mandate Expansion
29 Sep, 2016 Disclosure of Interests
29 Sep, 2016 Trendlines Completes Successful Sale of E.T.View Medical
29 Sep, 2016 September 2016 Update
28 Sep, 2016 E.T. View Medical Concludes Merger with Ambu A/S
15 Sep, 2016 Grant of Options
15 Sep, 2016 Announcement of Transition – Dr. Eran Feldhay
15 Sep, 2016 Announcement of Appointment – Dr Nitza Kardish
08 Sep, 2016 Clarification on Purchase of Shares by Chairmen
08 Sep, 2016 B.Braun Investment in Trendlines Medical Singapore
01 Sep, 2016 August 2016 Update
31 Aug, 2016 Trendlines Commences ADR Trading on OTCQX
31 Aug, 2016 Purchase of Company Shares by Chairmen
24 Aug, 2016 Disclosure of Directors’ Interests
11 Aug, 2016 Grant of Options Pursuant to Trendlines 2015 Share Option Plan
11 Aug, 2016 Q2 2016 Unaudited Financial Results
10 Aug, 2016 Q2 2016 Earnings Press Release
09 Aug, 2016 Invitation to Q2 Results Conference Call
02 Aug, 2016 SGM Results
01 Aug, 2016 July 2016 Update
18 Jul, 2016 Establishment of Trendlines Medical Singapore
04 Jul, 2016 June 2016 Update
27 Jun, 2016 SGM Announcement and Circular
22 Jun, 2016 Definitive Agreement on Sale of E.T.View
21 Jun, 2016 Expansion of Trendlines Medical OCS Mandate
17 Jun, 2016 Trendlines Negotiations Towards Sale of E.T.View
17 Jun, 2016 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer
02 Jun, 2016 May 2016 Update
16 May, 2016 Trendlines Launches ADR Program
11 May, 2016 Q1 2016 Financial Results Press Release
11 May, 2016 Q1 2016 Unaudited Financial Results
11 May, 2016 Q1 2016 Results Presentation
03 May, 2016 April 2016 Update
19 Apr, 2016 AGM Results
19 Apr, 2016 AGM 2016 Presentation
18 Apr, 2016 Bayer Trendlines Ag Innovation Fund
28 Mar, 2016 FY 2015 Annual Report
17 Mar, 2016 Clarification to Business Times Article
16 Mar, 2016 Results of Incubator Tender
15 Mar, 2016 Announcement of Appointment – Moshe Katzenelson
14 Mar, 2016 Financial Highlights Updated March 2016
14 Mar, 2016 Investor Presentation March 2016
03 Mar, 2016 AGM Notice
01 Mar, 2016 Additional Purchase Order from U.S-based Medical Device Public Company
01 Mar, 2016 February 2016 Update
01 Mar, 2016 Definitive Collaboration Agreement with B.Braun
25 Feb, 2016 Financial Highlights 2015-2016 Presentation
25 Feb, 2016 SGM Results Feb 2016
25 Feb, 2016 Investor Presentation February 2016
24 Feb, 2016 FY2015 Unaudited Results Press Release
24 Feb, 2016 FY 2015 Unaudited Financial Results
16 Feb, 2016 Clarification to a Publication by The Straits Times
11 Feb, 2016 Trendlines Signs Agreement with Japanese Medical Company
01 Feb, 2016 Trendlines January Update
19 Jan, 2016 SGM Notice and Circular
18 Jan, 2016 Trendlines Negotiates MOU with MNC
18 Jan, 2016 2015 Trendlines Highlights
13 Jan, 2016 Investor Presentation January 2016
05 Jan, 2016 Allotment and Issuance of Shares
30 Dec, 2015 Grant of Options
22 Dec, 2015 Trendlines Agtech Submits Tender Bid
17 Dec, 2015 Trendlines Medical Renews Incubator Franchise
17 Dec, 2015 The Trendlines Group Establishes Two New Companies
09 Dec, 2015 Saviva Capital LLC Commits To Participate in Trendlines Bid for Israel Government Incubator Franchise
26 Nov, 2015 Trading Debut for Trendlines as the 100th Listing on Catalist
24 Nov, 2015 Successful Completion of IPO
16 Nov, 2015 Prospectus
Corporate Governance

Trendlines shares were listed for trade on SGX on 26 November 2015

For full information on our Corporate Governance, see the FY2021 Annual Report.

The Trendlines Group Ltd. (the “Company” or the “Group”) recognizes the importance of corporate governance and the offering of high standards of accountability to the shareholders of the Company. Good corporate governance establishes and maintains a legal and ethical environment in the Group to protect the interests of the shareholders and to maximize long-term shareholders’ value.

The Company has implemented the Code of Corporate Governance and the accompanying Practice Guidance (the “2018 Code”), subject however to compliance with the various corporate governance requirements under the Israeli Companies Law (the “Israeli Companies Law”) with which the Company, as a company incorporated in Israel whose shares are publicly traded on a stock exchange, is required to comply.

Board Matters

The Board of Directors of the Company (the “Board”) comprises two Executive Directors and six Non-Executive Directors, out of which five are Independent Directors. The Board have the appropriate core competencies and diversity of experience to enable them, in their collective wisdom, to contribute effectively to the Group.

The Independent Directors are also the non-executive Directors of the Company. They come from different professions and working backgrounds, bringing their wealth of knowledge, business expertise and contacts in the business community to the Company, and play an important role in helping the Company to shape its business strategy by allowing the Company to draw on their diverse backgrounds and working experience.

Additionally, under Israeli Companies Law, shareholders of public companies must elect, by a disinterested majority (as defined under the Israeli Companies Law), at least two members of the Board who qualify as “External Directors” under the Israeli Companies Law. External Directors must meet certain standards of independence at the time of their appointment and during the two-year period prior to their appointment. Under Israeli Companies Law, at least one of the External Directors must have “accounting and financial expertise” and the rest of the External Directors must have either “professional competence” or “accounting and financial expertise”.

Under the Israeli Companies Law and its regulations, a company’s CEO may serve as the chair of the board of directors of such a company, subject to the required approvals, including shareholders’ approval with a special majority, to be renewed following a period of 5 years as of the date on which the Company’s shares were first offered to the public, and thereafter every 3 years, as required under the Israeli Companies Law and its regulations.

Because the CEOs, Messrs. David Todd Dollinger and Stephen Louis Rhodes, also serve as Chairs of the Board as detailed above, and thereby are not considered Independent Directors, the Company is required under the 2018 Code to designate an Independent Director to serve as Lead Independent Director. The Company has appointed Ms. Elka Nir to serve as its Lead Independent Director. The Lead Independent Director is available to the shareholders where they have concerns and for which contact through the normal channels of the Chairman and CEO or the Chief Financial Officer (or equivalent) has failed to resolve or is inappropriate or inadequate.

Matters reserved for the Board’s decision are specified in detail under the Israeli Companies Law and the Company’s Articles of Association (the “Articles”), which provide that the Company’s business and affairs are managed under the direction and oversight of the Board, which may exercise all powers and may take all actions that are not specifically granted to the shareholders or to any other organ of the Company. The Board determines the Company’s policy and supervises the performance of the Chief Executive Officers’ (the “CEOs”) duties and actions and is authorized, amongst other things, to:

  • determine the Company’s business plans, principles for funding them and the priorities between them;
  • review the financial status and determine the credit the Company is authorized to obtain;
  • determine the Company’s organizational structure and remuneration policy;
  • resolve to issue a series of debentures;
  • report to the Company’s shareholders on the status of the Company’s affairs and the results of its business operations at its annual general meetings (“AGM”);
  • appoint and remove the CEO(s);
  • resolve whether to approve (or disapprove) certain transactions, which require the approval of the Board under the Israeli Companies Law or the Articles;
  • issue securities and securities convertible into shares up to the limit of the Company’s authorized share capital;
  • resolve to effect a distribution in accordance with the Israeli Companies Law;
  • provide the Company’s opinion in respect of a special tender offer as stipulated in the Israeli Companies Law; and
  • determine the minimum number of Directors who should have accounting and financial expertise.

Apart from the matters that specifically require the Board’s approval as set forth above, the Board approves certain transactions of the Group exceeding certain threshold limits, while delegating authority for transactions below those limits to the Group’s management and/or the Group’s investment committees to optimize operational efficiency.

Our Board of Directors has established three (3) committees, namely, the Audit Committee, the Remuneration Committee, and the Nominating Committee.

These Board Committees have been constituted with clearly written terms of reference setting out the basic guiding principles for the establishment and activities of the respective Board Committees. Each Board Committee reviews and re-assesses the adequacy of its applicable terms of reference on an annal basis and submits such evaluation, including any recommendations for change, to the Board for consideration, review, discussion and approval. The Chairman of the respective Board Committees will report to the Board on the outcome of the Committee meetings and their recommendations on the specific agendas mandated to the Committee by the Board. The Board is ultimately responsible for the final decision on all matters.

In accordance with the Israeli Companies Law, every Director by virtue of his or her office occupies a fiduciary position with respect to the Company. A Director is not permitted to place him or herself in a situation where his or her interests conflict with his or her duty. If a director knows that he or she has a personal interest in an existing or proposed transaction of the Company, then he or she must disclose to the Company the nature of his personal interest, including any material fact or document.

Audit Committee

The Audit Committee composition is in compliance with the Israeli Companies Law following the election of the External Directors.

The Audit Committee is comprised of four Directors, all of whom, including the Chair, are Independent Directors who do not have any management and business relationships with the Company or any substantial shareholder of the Company. The Audit Committee includes the Company’s External Directors.

At its current composition, the Audit Committee comprises members who are appropriately qualified, having relevant accounting or related financial management expertise and experience to discharge the authority and duties delegated by the Board to the Audit Committee.

None of the Audit Committee members were previous partners or directors of the Company’s external audit firm within the last twenty-four months and none of the Audit Committee members hold any financial interest in the external audit firm.

The authority and duties delegated by the Board to the Audit Committee are detailed in written terms of reference approved by the Board, and include, inter alia:

  • Reviewing and recommending to the Board the approval of the Company’s half-yearly and annual financial statements and related management’s discussion and analysis;
  • Recommending to the Board and overseeing the external auditors of the Company, including reviewing the scope and results of the external audit, and the independence and objectivity of the external auditors;
  • Making recommendations to the Board on the proposals to the shareholders on the appointment, re- appointment and removal of the external auditors, and approving the remuneration and terms of engagement of the external auditors;
  • Reviewing the relevance and consistency of the accounting standards, the significant financial reporting issues, recommendations and judgments made by the external auditors so as to ensure the integrity of the financial statements of the Group and any announcements relating to the Group’s financial performance;
  • Pre-approving all audit and non-audit services to be provided to the Group by the external auditors;
  • Identifying deficiencies in the administration of the Company (including reviewing and reporting to the Board at least annually the adequacy and effectiveness of the Group’s internal controls, including financial, operational, compliance and information technology controls (such review can be carried out internally or with the assistance of any competent third parties), and recommending remedial actions with respect to such deficiencies;
  • Reviewing the effectiveness and adequacy of the Group’s internal audit function;
  • Reviewing the system of internal controls and management of financial risks with the internal and external auditors;
  • Reviewing the cooperation of the Company’s management with the external auditors and the internal auditors (without the presence of management), where applicable, and at least annually;
  • Reviewing the Group’s compliance with such functions and duties as may be required under the relevant statutes or the Catalist Rules, including such amendments made thereto from time to time;
  • Reviewing of hedging policies and instruments to be implemented (if any);
  • Reviewing and approving interested person transactions and review procedures thereof;
  • Reviewing potential conflicts of interest (if any) and to set out a framework to resolve or mitigate any potential conflicts of interests;
  • Reviewing the risk management framework, with a view to providing an independent oversight on the Group’s financial reporting, the outcome of such review to be disclosed in the annual reports or, where the findings are material, to announce immediately via SGXNET;
  • Investigating any matters within its terms of reference;
  • Reviewing the policy and arrangements by which the staff and any other parties may, in confidence, raise concerns about possible improprieties in matters of financial reporting and ensuring that arrangements are in place for the independent investigations of such matter and for appropriate follow-up;
  • Administering and overseeing the implementation of the Disclosure and Insider Trading Policy, the Whistle Blowing Policy, the Anti-Bribery Policy, and any other corporate policy as may be adopted by the Company;
  • Undertaking such other functions and duties as may be required by statute or the Catalist Rules, and by such amendments made thereto from time to time; and
  • Reviewing assurance from the CEO and CFO on the financial records and financial statements. In addition, under the Israeli Companies Law, the Audit Committee is required, amongst other things, to:
  • Identify deficiencies in the administration of the Company (including by consulting with the internal auditor or the external auditors of the Company), and recommend remedial actions with respect to such deficiencies;
  • Determine with respect to transactions with related parties, including office holders and the controlling shareholder (if any), if such transactions are substantial actions (i.e. an action that is likely to materially affect the Company’s profitability, assets or liabilities) or extraordinary transactions (i.e. a transaction that is not in a Company’s ordinary course of business, not on market terms or that is likely to have a material impact on the Company’s profitability, assets or liabilities) and may determine once a year, in advance, criteria for such determination;
  • Determine with respect to extraordinary (and non-extraordinary) transactions with the controlling shareholder, the requirement to conduct a competitive procedure, or other procedures to be conducted prior to entry into such transactions;
  • Review and approve or disapprove certain related-party transactions;
  • Determine the procedure for approval of transactions with the controlling shareholder, which are not negligible transactions;
  • Where the Board approves the working plan of the internal auditor, examine such working plan before its submission to the Board and proposing amendments thereto;
  • Examine the internal audit controls and internal auditor’s performance, including whether the internal auditor has sufficient resources and tools to fulfil his responsibilities;
  • Examine the scope of the external auditor’s work and compensation and submit recommendations with respect thereto to the Board or general meeting, depending on which of them is considering the remuneration of the external auditor; and
  • Adopt procedures with respect to processing employee complaints in connection with deficiencies in the administration of the Company, and the appropriate means of protection afforded to such employees.

 

Apart from the duties listed above, the Audit Committee shall commission and review the findings of internal investigations into matters where there is any suspected fraud or irregularity, or failure of internal controls or suspected infringement of any Israeli law, rule or regulation which has or is likely to have a material impact on the Group’s operating results and/or financial position.

The Audit Committee shall also commission an annual internal control audit until such time as the Audit Committee is satisfied that the Group’s internal controls are robust and effective enough to mitigate the Group’s internal control weaknesses (if any). The Company has established and maintains on an ongoing basis, an effective internal audit function that is adequately resourced and independent of the activities it audits.

Nominating Committee

The Nominating Committee comprises five Directors, a majority of whom are Independent Directors, including the Nominating Committee Chair. The Lead Independent Director is a member of the Nominating Committee.

The Nominating Committee is established, inter-alia, for the purposes of ensuring that the Company has a formal and transparent processes for all Board appointments, performance evaluation and professional development.

The authority and duties delegated by the Board to the Nominating Committee are detailed in written Terms of Reference approved by the Board, and include, inter alia:

  • Developing corporate governance guidelines and principles for the Company;
  • Identifying individuals qualified for nomination to the Board and reviewing and recommending the nomination or re-nomination of the Directors, with regard to the Director’s contribution and performance;
  • Considering the structure and composition of the Board and Board Committees;
  • Evaluating the performance and effectiveness of the Board, the Board Committees and each of their members;
  • Succession planning, including the appointment recommendations of Directors, Chairs and CEO and senior management;
  • Training and professional development program for Board members;
  • determining on an annual basis whether or not a Director is independent or whether an individual qualifies as an external director in accordance with the Israeli Companies Law; and and the 2018 Code;
  • reviewing and approving any new employment of related persons and the proposed terms of their employment, subject to the requirements under Israeli law; and
  • Recommending from time to time to the Board concerning such other matters, including matters related to corporate governance, as appropriate.

Each member of our Nominating Committee will not take part in determining his or her own re-nomination or independence and shall abstain from voting on any resolutions in respect of the assessment of his or her performance or re-nomination as a Director. In the event that any member of our Nominating Committee has an interest in a matter being deliberated upon by our Nominating Committee, he or she will abstain from participating in the review and approval process relating to that matter.

Remuneration Committee

Under the Israeli Companies Law, a public company must have a Remuneration Committee comprised of at least three directors, including all the external directors who must be the majority members and one must serve as the Chair of the committee. All remaining members must receive remuneration for their service as Directors of the Company, in accordance with the regulations under the Israeli Companies Law governing the remuneration of the external directors.  The  Remuneration Committee must  not  include  the  Chair (or  Chairs) of the Board,  any  controlling  shareholder  or a relative of a controlling shareholder or any director employed by the Company or by the Company’s controlling shareholder or by an entity under the control of the Company’s controlling shareholder, or a Director who provides services, on a regular basis, to the Company, to its controlling shareholder or to any entity under the control of such controlling shareholder, as well as any Director whose principal livelihood derives from the Company’s controlling shareholder. Our remuneration committee is comprised of three Directors, all of whom are Independent Directors, including the Remuneration Committee Chair.

The authority and duties delegated by the Board to the Remuneration Committee are detailed in written terms of reference approved by the Board, and include, inter alia:

  • Reviewing and making recommendations to the Board with respect to the approval of the compensation policy with respect to the terms of office and employment of office holders and any extensions thereof;
  • Periodically reviewing the implementation of the compensation policy and providing the Board with recommendations with respect to any amendments or updates thereto;
  • Reviewing and resolving whether or not to approve arrangements with respect to the terms of office and employment of office holders;
  • Determining whether or not to exempt a transaction with a candidate for CEO from shareholders’ approval because such approval would preclude the engagement with such a candidate, provided that such transaction is consistent with the compensation policy;
  • Overriding a determination of the shareholders in relation to certain compensation related issues, subject to the approval of the Board and under special circumstances, such as, the approval of the Company’s compensation policy, after such compensation policy was reconsidered by the Remuneration Committee and on the basis of detailed reasons, the Remuneration Committee and thereafter the Board determined that the adoption of the compensation policy is in the best interests of the Company despite the objection of the shareholders;
  • The establishment of key human resources and compensation policies, including all incentive and equity- based compensation plans;
  • Evaluating the Company’s executive and senior management; and
  • Recommending to the Board a framework of remuneration for the Directors and other office holders, including KMPs, and determining specific remuneration packages for each Director and office holder, including, without limitation, directors fees, salaries, allowances, bonuses, benefits in kind, pension rights, compensation payments (including any compensation payable for loss or termination of office, service or appointment), incentive payments, options and share-based incentives and awards.

In addition, the Remuneration Committee will perform an annual review of the remuneration of both employees who are substantial shareholders of the Company and employees related to the Directors and/or substantial shareholder of the Company (as defined in the Catalist Rules) to ensure that their remuneration packages are fair and reasonable and in line with the Company’s staff remuneration guidelines and commensurate with their respective job scopes and level of responsibilities. The Remuneration Committee will also review and approve any bonuses, pay increases and/or promotions for these employees.

Shareholder Rights and Engagement

The Company encourages shareholders’ participation at the general meetings of its shareholders. All shareholders are entitled to attend and vote at general meetings in person or by proxy. The rules including the voting procedures are set out in the notice of general meetings, which are dispatched to shareholders via the SGXNet and on the Company’s website. A polling agent is appointed by the Company for general meetings who will explain the rules, including the voting procedures, that govern the general meetings of shareholders. All polling procedures are scrutinized by an independent scrutineer.

Being committed to good corporate practices, the Company treats all its shareholders fairly and equitably. To facilitate the exercise of shareholders’ rights, the Company ensures that all material information relating to the Group and its financial performance is disclosed in an accurate and timely manner via the SGXNet.

The Company ensures that its shareholders are notified of all material information in an accurate and timely manner. The Company’s unaudited, half-yearly and annual results are announced within the mandatory period prescribed by the Catalist Rules. The financial statements and other materials presented at the Company’s general meetings, including material and price-sensitive information, are disseminated, and publicly released via the SGXNet on a timely basis. All shareholders receive the annual report of the Company and the notice of the Company’s AGMs, which is also made publicly available in the press and released via the SGXNet. Shareholders and investors may contact the Company or access information regarding the Company on its website which provides, inter alia, corporate announcements, press releases, the latest financial results and presentations as released by the Company on the SGXNet, and contact details of its investor relations service provider.

Shira Zimmerman
Investor Communications
The Trendlines Group
investors@trendlines.com
Skip to content